Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Table of Contents

What We're Reading

  • What We're Reading
    A Sampling of Highlights from the Literature
    Cancer Immunol Res April 1 2019 7 (4) 527-527;

Cancer Immunology at the Crossroads

  • Cancer Immunology at the Crossroads
    Adoptive Immunotherapy with Antigen-Specific T Cells Expressing a Native TCR
    Wingchi Leung and Helen E. Heslop
    Cancer Immunol Res April 1 2019 7 (4) 528-533; DOI:10.1158/2326-6066.CIR-18-0888

Cancer Immunology Miniature

  • Cancer Immunology Miniature
    Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer
    Winifred Lo, Maria Parkhurst, Paul F. Robbins, Eric Tran, Yong-Chen Lu, Li Jia, Jared J. Gartner, Anna Pasetto, Drew Deniger, Parisa Malekzadeh, Thomas E. Shelton, Todd Prickett, Satyajit Ray, Scott Kivitz, Biman C. Paria, Isaac Kriley, David S. Schrump and Steven A. Rosenberg
    Cancer Immunol Res April 1 2019 7 (4) 534-543; DOI:10.1158/2326-6066.CIR-18-0686

    A patient with metastatic colon cancer had T-cell receptors reactive with a mutation in the tumor suppressor gene TP53. The TCRs were neoantigen-specific and HLA-A*0201-restricted and could be used to treat others with tumors sharing the same parameters.

Priority Briefs

  • Priority Briefs
    Early-Life Microbiota Exposure Restricts Myeloid-Derived Suppressor Cell–Driven Colonic Tumorigenesis
    Akihito Harusato, Emilie Viennois, Lucie Etienne-Mesmin, Shingo Matsuyama, Hirohito Abo, Satoru Osuka, Nicholas W. Lukacs, Yuji Naito, Yoshito Itoh, Jian-Dong Li, Didier Merlin, Andrew T. Gewirtz and Timothy L. Denning
    Cancer Immunol Res April 1 2019 7 (4) 544-551; DOI:10.1158/2326-6066.CIR-18-0444

    Mice with altered colon microbiota early in life exhibit augmented inflammatory cytokine and chemokine expression in the colon. This led to an increased susceptibility to colitis-associated cancer later in adulthood, demonstrating the microbiota's impact on colon homeostasis.

  • Priority Briefs
    Broad Cytotoxic Targeting of Acute Myeloid Leukemia by Polyclonal Delta One T Cells
    Biagio Di Lorenzo, André E. Simões, Francisco Caiado, Paola Tieppo, Daniel V. Correia, Tânia Carvalho, Maria Gomes da Silva, Julie Déchanet-Merville, Ton N. Schumacher, Immo Prinz, Haakan Norell, Sarina Ravens, David Vermijlen and Bruno Silva-Santos
    Cancer Immunol Res April 1 2019 7 (4) 552-558; DOI:10.1158/2326-6066.CIR-18-0647

    This study provides preclinical in vitro and in vivo proof-of-concept for use of Delta One T (DOT) cells as immunotherapy to treat acute myeloid leukemia.

Research Articles

  • Research Articles
    CD96 Is an Immune Checkpoint That Regulates CD8+ T-cell Antitumor Function
    Deepak Mittal, Ailin Lepletier, Jason Madore, Amelia Roman Aguilera, Kimberley Stannard, Stephen J. Blake, Vicki L.J. Whitehall, Cheng Liu, Mark L. Bettington, Kazuyoshi Takeda, Georgina V. Long, Richard A. Scolyer, Ruth Lan, Nathan Siemers, Alan Korman, Michele W.L. Teng, Robert J. Johnston, William C. Dougall and Mark J. Smyth
    Cancer Immunol Res April 1 2019 7 (4) 559-571; DOI:10.1158/2326-6066.CIR-18-0637

    The antitumor activity of anti-CD96 monotherapy depends on several host factors, including CD8+ T cells and immune signaling. Inhibition of CD96 in combination with other immune checkpoint inhibitors shows superior antitumor activity over single or dual agent therapy.

  • Research Articles
    Targeted Delivery of IL2 to the Tumor Stroma Potentiates the Action of Immune Checkpoint Inhibitors by Preferential Activation of NK and CD8+ T Cells
    Cornelia Hutmacher, Nicolás Gonzalo Núñez, Anna Rita Liuzzi, Burkhard Becher and Dario Neri
    Cancer Immunol Res April 1 2019 7 (4) 572-583; DOI:10.1158/2326-6066.CIR-18-0566

    Treatment of murine tumors with combination checkpoint blockade and an antibody-IL2 fusion protein reduces tumor growth, an effect dependent on CD8+ T cells and NK cells. These data support the use of engineered IL2 products for anti-cancer therapy.

  • Research Articles | AuthorChoice
    Sustained Type I Interferon Reinforces NK Cell–Mediated Cancer Immunosurveillance during Chronic Virus Infection
    Ji Hoon Oh, Myeong Joon Kim, Seong Jin Choi, Young Ho Ban, Heung Kyu Lee, Eui-Cheol Shin, Kyung-Mi Lee and Sang-Jun Ha
    Cancer Immunol Res April 1 2019 7 (4) 584-599; DOI:10.1158/2326-6066.CIR-18-0403

    Chronic LCMV infection delays tumor progression as a result of sustained type I IFN signaling and enhanced NK cell–mediated immunosurveillance. This observation could improve the development of effective treatment strategies for cancer patients with chronic viral infections.

  • Research Articles
    Regulatory T Cells in an Endogenous Mouse Lymphoma Recognize Specific Antigen Peptides and Contribute to Immune Escape
    Fatima Ahmetlić, Tanja Riedel, Nadine Hömberg, Vera Bauer, Nico Trautwein, Albert Geishauser, Tim Sparwasser, Stefan Stevanović, Martin Röcken and Ralph Mocikat
    Cancer Immunol Res April 1 2019 7 (4) 600-608; DOI:10.1158/2326-6066.CIR-18-0419

    In a mouse model of B-cell lymphoma, regulatory T cells suppressed antitumor responses. Treg cells recognized nonmutated self epitopes, which were characteristic of lymphoma and which were related to malignancy.

  • Research Articles
    Automated Analysis of Lymphocytic Infiltration, Tumor Budding, and Their Spatial Relationship Improves Prognostic Accuracy in Colorectal Cancer
    Ines P. Nearchou, Kate Lillard, Christos G. Gavriel, Hideki Ueno, David J. Harrison and Peter D. Caie
    Cancer Immunol Res April 1 2019 7 (4) 609-620; DOI:10.1158/2326-6066.CIR-18-0377

    Automated image analysis reveals that high tumor bud numbers, low T-cell density, and few T cells proximal to tumor buds were associated with reduced survival of CRC patients. This model provided greater prognostic value than current clinical guidelines.

  • Research Articles
    Intravesical Ty21a Vaccine Promotes Dendritic Cells and T Cell–Mediated Tumor Regression in the MB49 Bladder Cancer Model
    Sonia Domingos-Pereira, Karthik Sathiyanadan, Stefano La Rosa, Lenka Polák, Mathieu F. Chevalier, Paul Martel, Rim Hojeij, Laurent Derré, Jacques-Antoine Haefliger, Patrice Jichlinski and Denise Nardelli-Haefliger
    Cancer Immunol Res April 1 2019 7 (4) 621-629; DOI:10.1158/2326-6066.CIR-18-0671

    Low-dose intravesical administration of Ty21a, a commercial typhoid vaccine, generated effective antitumor DC and T-cell responses and improved survival in a mouse model of bladder cancer. These results demonstrate the potential of Ty21a for clinical use.

  • Research Articles
    Low-Dose Apatinib Optimizes Tumor Microenvironment and Potentiates Antitumor Effect of PD-1/PD-L1 Blockade in Lung Cancer
    Sha Zhao, Shengxiang Ren, Tao Jiang, Bo Zhu, Xuefei Li, Chao Zhao, Yijun Jia, Jinpeng Shi, Limin Zhang, Xiaozhen Liu, Meng Qiao, Xiaoxia Chen, Chunxia Su, Hui Yu, Caicun Zhou, Jun Zhang, D. Ross Camidge and Fred R. Hirsch
    Cancer Immunol Res April 1 2019 7 (4) 630-643; DOI:10.1158/2326-6066.CIR-17-0640

    Both preclinical and phase IB clinical data indicate that lower-than-conventional doses of the anti-angiogenic agent apatinib (a VEGFR2-TKI) optimized the immunosuppressive tumor microenvironment and potentiated the therapeutic response to anti-PD-1/PD-L1 immunotherapy in lung cancer.

  • Research Articles
    Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL
    Ziju Y. Xu-Monette, Min Xiao, Qingyan Au, Raghav Padmanabhan, Bing Xu, Nicholas Hoe, Sandra Rodríguez-Perales, Raul Torres-Ruiz, Ganiraju C. Manyam, Carlo Visco, Yi Miao, Xiaohong Tan, Hongwei Zhang, Alexandar Tzankov, Jing Wang, Karen Dybkær, Wayne Tam, Hua You, Govind Bhagat, Eric D. Hsi, Maurilio Ponzoni, Andrés J.M. Ferreri, Michael B. Møller, Miguel A. Piris, J. Han van Krieken, Jane N. Winter, Jason R. Westin, Lan V. Pham, L. Jeffrey Medeiros, George Z. Rassidakis, Yong Li, Gordon J. Freeman and Ken H. Young
    Cancer Immunol Res April 1 2019 7 (4) 644-657; DOI:10.1158/2326-6066.CIR-18-0439

    The immune profile of the tumor microenvironment in DLBCL patients was assessed with a MultiOmyx platform. PD-1/L1 expression on T cells and PD-L1 expression on macrophages had prognostic value in identification of patients with poor survival after immunochemotherapy.

  • Research Articles
    Autologous Lymphocyte Infusion Supports Tumor Antigen Vaccine–Induced Immunity in Autologous Stem Cell Transplant for Multiple Myeloma
    Adam D. Cohen, Nikoletta Lendvai, Sarah Nataraj, Naoko Imai, Achim A. Jungbluth, Ioanna Tsakos, Adeeb Rahman, Anna Huo-Chang Mei, Herman Singh, Katarzyna Zarychta, Seunghee Kim-Schulze, Andrew Park, Ralph Venhaus, Katherine Alpaugh, Sacha Gnjatic and Hearn J. Cho
    Cancer Immunol Res April 1 2019 7 (4) 658-669; DOI:10.1158/2326-6066.CIR-18-0198

    Immunotherapy can include vaccines in the setting of autologous stem cell transplantation for multiple myeloma. Here, autologous lymphocyte infusion augmented immunotherapy and supported humoral and CD4+ helper T-cell immunity in response to a therapeutic tumor vaccine.

  • Research Articles
    Radiotherapy and Cisplatin Increase Immunotherapy Efficacy by Enabling Local and Systemic Intratumoral T-cell Activity
    Paula Kroon, Elselien Frijlink, Victoria Iglesias-Guimarais, Andriy Volkov, Marit M. van Buuren, Ton N. Schumacher, Marcel Verheij, Jannie Borst and Inge Verbrugge
    Cancer Immunol Res April 1 2019 7 (4) 670-682; DOI:10.1158/2326-6066.CIR-18-0654

    The response to PD-1 blockade and CD137 agonism could be improved by “re-purposing” radiotherapy or cisplatin to modulate the tumor microenvironment. Chemo/radio-immunotherapy enhances CTL responses, tumor regression, and survival in a mouse model of poorly immunogenic breast cancer.

  • Research Articles
    T-cell Activity against AML Improved by Dual-Targeted T Cells Stimulated through T-cell and IL7 Receptors
    Eric Krawczyk, Sergey N. Zolov, Kevin Huang and Challice L. Bonifant
    Cancer Immunol Res April 1 2019 7 (4) 683-692; DOI:10.1158/2326-6066.CIR-18-0748

    An engineered T cell specific for two antigens shows anti-AML activity. Combining CD123 recognition and IL7R activation enhances antitumor activity and T-cell survival in preclinical models, suggesting the value of extending this strategy to other tumor types.

Correction

  • Correction | Free Article
    Correction: Collapse of the Plasmacytoid Dendritic Cell Compartment in Advanced Cutaneous Melanomas by Components of the Tumor Cell Secretome
    Cancer Immunol Res April 1 2019 7 (4) 693-693; DOI:10.1158/2326-6066.CIR-19-0108

Back to top
PreviousNext
Cancer Immunology Research: 7 (4)
April 2019
Volume 7, Issue 4
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

Jump to

  • What We're Reading
  • Cancer Immunology at the Crossroads
  • Cancer Immunology Miniature
  • Priority Briefs
  • Research Articles
  • Correction
Advertisement
  • Most Cited
  • Most Read
Loading
  • Activity of Anti-CTLA-4 Isotypes in Antitumor Responses
  • Masters of Immunology
  • Extending Reach of Checkpoint Blockade in Pancreatic Cancer
  • PD-L1 in Triple-Negative Breast Cancer
  • Case Report: RNA CAR T Cells
More...
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement